9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant (Pleural) Mesothelioma

Estimated Enrollment: 10

Gender: All

Min Age:

Age Group: Child, Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: number of cytotoxic T cells and regulatory T cells in the blood of patients,  safety and toxicity,  ,

Interventions: DC + CTX,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: October 2011

Completion Date: October 2012

Last  Posted Date: February 27, 2014

Location: Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands

Website Link: https://ClinicalTrials.gov/show/NCT01241682

Was this article helpful?
Dislike 0